Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Rentschler Group
Rentschler Group
Activities:
Manufacturing
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Manufacturing
Rentschler Biopharma contributes to nearly 25% of FDA approved biopharmaceuticals in 2023
Exceptional capabilities in guiding therapies from early stage development through to market based on more than 50 years of biotech experience
Manufacturing
Rentschler Biopharma announces major client project for new US facility
State-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) facility slated to open for business next year
Manufacturing
Dr Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma
Rentschler Biopharma announces that Dr Günter Stempfer has been appointed Site Head of the company’s facility in Laupheim, Germany, effective 1 December 2023
Manufacturing
Rentschler receives MHRA approval for AAV vector facility
The CDMO has received a cGMP following an MHRA visit to its UK site, now set for clinical production of adeno-associated virus (AAV) vectors for gene therapy
Drug Delivery
Rentschler partners with Ikarovec on treatment for ophthalmic disease
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UK
Manufacturing
Rentschler Biopharma appoints Head of Digital Manufacturing and Automation
Before joining Rentschler Biopharma, Thomas aus dem Siepen worked for 16 years in management positions at Roche Diagnostics
Manufacturing
Rentschler awarded in CDMO Leadership Awards
The CDMO Leadership Awards Ceremony and Reception will be held in New York City on March 22, 2023
Subscribe now